Complement C9 Monoclonal Antibody (C9 53), Invitrogen™

Description

• ABS 004-53-02 is specific for complement factor C9
• ABS 004-53-02 recognizes C9 in human serum diluted 1:50 in Tris buffer (20 mM Tris-base, 1 mM MgCl2, 1 mM CaCl2 and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 μg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour) ELISA plate
• NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum
• Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex
• The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane
• During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components
• The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane
• The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive
• C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage
• Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.